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Abstract
Background. To determine whether classic analgesic
nephropathy with renal papillary and urothelial
capillary sclerosis could still be detected at autopsy in
the beginning of the 21st century, the present study
which is similar to a previous one performed in 1980
was undertaken as suggested by the Ad Hoc
Committee of the International Study Group on
Analgesics and Nephropathy.
Methods. Consecutive autopsies of 616 adults per-
formed at the Basle Institute of Pathology between
November 2000 and February 2002 were analysed.
Tissue samples of renal cortex and papilla of 1220
kidneys and of each ureter and main renal artery
available were subjected to a very careful and
meticulous study using classical histopathological
methodology.
Results. A number of lesions was found macroscopi-
cally but not a single case of papillary necrosis or
analgesic nephropathy could be detected preceding
histological analysis. Histologically, the most frequent
lesions were vascular in 57.8% of kidneys followed by
glomerular lesions in 13.1% (mostly diabetic glomerulo-
sclerosis). Tubulo-interstitial lesions, mostly pyelone-
phritis were detected in 9.3% with only a single case of
classic analgesic nephropathy with bilateral complete
papillary necrosis and ureteral capillary sclerosis in a
female who had received a renal transplant 14 years
before her demise at the age of 67. In another five cases,
complete papillary necrosis was detected associated
with pyelonephritis, hydronephrosis or in completely
shrunken kidneys. However, in the absence of capillary
sclerosis, a histopathological diagnosis of classic
analgesic nephropathy could not be made in any of
these five cases.
Conclusions. The Basle autopsy prevalence of analgesic
nephropathy decreased continuously from some 3% in
1980 to 0.2% in 2000 as shown by the present study.
Similarly, capillary sclerosis of the urinary tract, the
initiating event in the pathophysiology of papillary
necrosis and analgesic nephropathy and the
histological hallmark of the effect of toxic metabolites
of phenacetin in analgesic abusers decreased from 4%
of autopsy cases between 1978 and 1980 to the
single case of the present study observed at the end
of 2000. Thus, the classic analgesic nephropathy
has disappeared some 20 years after the removal of
phenacetin from the analgesic market despite the fact
that mixed analgesics containing paracetamol, the
main metabolite of phenacetin, have continued to be
popular and widely used drugs.
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Introduction
The history of analgesic nephropathy is closely
intertwined with that of papillary necrosis and
the discovery and use of analgesics. The simple
analgesics—salicylic acid, pyrazolones, phenacetin,
paracetamol—were discovered toward the end of the
19th century and were soon introduced into clinical
medicine [1]. Since the beginning of the 20th century,
it has been known that overdosage of these drugs can
result in disorders of renal function. As long as the
analgesics concerned were taken as single drugs, they
caused acute complications but no long-term side
effects. In the 1940s and early 1950s, after the addition
of caffeine and the introduction of combined prepara-
tions intended to optimize their effectiveness and
minimize side effects [2], the consumption of analgesics
became widespread and also addictive [3].
In 1950, 1953 and 1955, Spu¨hler and Zollinger [4–8]
described unusual forms of chronic interstitial
nephritis which they first associated with the use of
sulfonamides and later correctly with excessive
intake of phenacetin-containing analgesics. Its patho-
genetic history is best illustrated by the study of
Gloor [9–11] in Basle. In the period from 1938 to 1942,
only 2.7% of all patients with autopsy evidence
of chronic interstitial nephritis had papillary
necrosis, whereas in the period from 1958–1962 the
corresponding figure was 57%. A number of
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investigations contributed to the elucidation of the
pathological entity we have come to know as analgesic
nephropathy. Spu¨hler and Zollinger [7] mistakenly
assumed the condition to be primarily a form of
chronic interstitial nephritis. Gloor and Burry et al.
[9–12] were the first to regard papillary necrosis as the
primary lesion. Sanerkin and Kincaid-Smith [13,14]
interpreted the interstitial nephritis as a consequence
and not as a cause of the papillary necrosis. Not
until the 1970s was capillary sclerosis recognized by
Munck et al., Abrahams et al. and Torhorst [15–17]
as an additional pathological feature of the condition.
A number of Scandinavian pathologists and clinicians
further contributed to the elucidation of the disease
[18–25]. Finally, Mihatsch et al. [26,27] proved that
capillary sclerosis is the cause of papillary necrosis
and a pathognomonic lesion in analgesic nephropathy
due to the abuse of phenacetin-containing mixed
analgesics.
It was not until 1984 that analgesic nephropathy
was recognized universally as an analgesic-associated
disease [28]. Hultengren et al. [29] reported the
occurrence of urinary tract tumours in analgesic
abusers 12 years after the first description of analgesic
nephropathy. Nanra et al. [30] integrated the broad
range of adverse effects under the term analgesic
syndrome consisting of analgesic nephropathy, urinary
tract tumours and other disturbances.
At the time of our last review, classic analgesic
nephropathy was defined as a bilateral chronic renal
disease characterized by papillary necrosis, chronic
interstitial nephritis, renal cortical atrophy, capillary
sclerosis and sometimes a brownish discoloration of
the renal papillae and the mucosa of the urinary tract
[31]. At that time the authors believed that analgesic
nephropathy was due to mixed analgesics containing
(i) phenacetin or paracetamol; (ii) salicylates or other
components (phenazone, pyrazole) and (iii) caffeine,
codein or barbiturates. This chronic nephropathy
has to be distinguished from other renal disorders
caused by modern analgesics including non-steroidal
anti-inflammatory drugs (NSAIDs).
By 1980, analgesic nephropathy as a cause of end-
stage renal disease reached peak proportions of around
20% of all the patients starting renal replacement
therapy in Belgium and in Australia, while its incidence
had already declined in Denmark and quite dramati-
cally in Sweden where legislation to remove phenacetin
from the analgesic market had been introduced in the
early 1960s [32,33]. In Switzerland, in 1980, over 25%
of the patients starting renal replacement therapy
suffered from analgesic nephropathy [32,33]. At the
same time, based on the finding of capillary sclerosis
in the ureter the prevalence of prior abuse of
phenacetin containing analgesics in the Basle autopsy
population was estimated to be about 4% overall and
twice as high in women as in men [34–36]. At last in
1981, because of the high prevalence of analgesic
nephropathy and urothelial cancer in patients with
analgesic abuse, phenacetin was banned from mixed
analgesics to disappear completely from Swiss
pharmacies and drugstores by the end of 1983. At
that time one of the authors (M.J.M.) found the legal
measures insufficient because in contrast to the other
author (F.P.B.) he favoured the hypothesis that
paracetamol, the major metabolite of phenacetin,
taken in combination with salicylates might have
been the main culprit in the pathogenesis of analgesic
nephropathy.
Despite the unrestricted sale of mixed analgesics
containing paracetamol, salicylates and caffeine,
a steady decrease in the prevalence of analgesic
nephropathy had occurred in Sweden and other
countries [33] and had also been noticed at autopsy
in Basle. Urothelial tumours of the renal pelvis or the
ureter decreased as well. However, Elseviers and De
Broe [37] in Belgium reported a persistently high
prevalence of analgesic nephropathy in patients on
renal replacement therapy, which they attributed to the
use of mixed analgesics no longer containing
phenacetin.
The controversy regarding the nephrotoxic potential
of these newer mixed analgesic preparations was
the reason for setting up the ‘Ad Hoc Committee
of the International Study Group on Analgesics and
Nephropathy’ and the authors of the present report
were asked to perform an autopsy study similar to the
one in 1980 [36] to answer the following questions [38]:
(a) Is the classical picture of analgesic nephropathy as
defined above still a frequent finding at autopsy?
(b) Is capillary sclerosis as pathognomonic marker of
phenacetin containing analgesics still detected at
autopsy?
Patient population and methods
Consecutive autopsies of 616 adults (older than 20 years)
performed between November 2000 and February 2002 were
evaluated systematically. The following variables were
recorded: age, sex, body height and weight, body mass
index and serum creatinine in mmol/l (representative baseline
value within the last week before death). The following
kidney parameters were systematically determined: kidney
weight (after removing the renal capsule), semiquantitative
determination of superficial renal scars (in percent of renal
surface) after coronary sectioning of the kidneys, presence or
absence of papillary necroses.
In general, for the histological study, two tissue blocks
encompassing cortex and papilla were obtained from each
kidney and in addition tissue blocks from the most severely
affected kidney areas. Three tissue samples were taken
from each ureter (proximal, middle and distal part) and
a longitudinal section of each main renal artery. The tissue
sections were embedded in paraffin and 3 mm thick sections
were stained: kidney sections with HE, PAS, AFOG
(trichrome) and Elastica van Gieson; ureter with PAS;
renal artery with HE and Elastica van Gieson.
All sections were evaluated by B.K. and in the case of
pathological or uncertain findings, also by M.J.M. All
diagnoses were recorded separately for the right and the
left kidney.
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Results
Patient population and kidney parameters
Consecutive autopsies were performed in 323 males
and 293 females. Median age of all patients was
77 years (males 75, females 80) (Table 1). Body mass
index (median 23.8) showed slightly greater variation
in females compared to males.
The median kidney weight was 130 g for the right
and 132 g for the left kidney. Male kidneys weighed
some 40 g more than female kidneys. The majority
(52%) of the kidneys failed to show superficial scars.
For kidneys with superficial scars, the average scarred
surface area was 57 42% (median 60%) for both
males and females. No correlation of kidney weight
and scarred surface area respectively with renal
function was found (data not shown). Serum creatinine
values were available in 90% of the patients. With
median serum creatinine concentrations of 122 mmol/l
for males (n¼ 284) and 107mmol/l for females
(n¼ 263), the renal function appeared to have been
normal up to the last week preceding death in close to
50% of the patients. Not in a single case could
papillary necrosis or analgesic nephropathy be diag-
nosed macroscopically.
Histological findings
The prevalence of different types of renal lesions is
summarized in Table 2. As shown, 15% showed no
significant abnormalities at all, 16% more than one
lesion, 70% of the kidneys had histological evidence of
chronic lesions and 8.3% showed acute lesions such
as signs of shock kidney (5%), pyelonephritis (3%) or
others (each <1%). Tumours were recorded in 5.8%
of the kidneys. The majority of tumours was metastatic
(3%) followed by benign tumours (2.5%). Primary
malignant tumours were found in a total of 13 patients
(including prior nephrectomy). Ureteral pathology
was found in 1.5% of the ureters of which metastatic
tumours were the most prevalent (0.7%).
The predominant type of chronic pathology
(Table 3) were vascular lesions (57.8%), mainly
vascular scars in 55.1% of the kidneys followed in
frequency by glomerular lesions (mostly diabetic
glomerulosclerosis). Tubulo-interstitial lesions were
found in 9.3% of the kidneys (mainly pyelonephritis)
and metabolic lesions in 6.6% (mainly nephro-
calcinosis of minor degree in 5.5%).
Papillary pathology is summarized in Table 4.
Significant papillary lesions were absent from 85.7%
of the kidneys. Fibrosis, mostly focal, was recorded in
7.4%. Papillary necroses (Figure 1) present in 8.4%
of the kidneys were in the great majority areactive
focal necroses of the papillary tip or of the medulla
intermediate between the cortico-medullary junction
Table 3. ‘Chronic’ renal lesions in 616 patients/1220 kidneys
Diagnosis Both sides n
(% of kidneys)
No significant chronic lesions 366 (30)
Predominant glomerular lesions 160 (13.1)
Glomerulonephritis 24 (2.0)
Diabetic diffuse glomerulosclerosis 38 (3.1)
Diabetic nodular glomerulosclerosis 67 (5.5)
Glomerulosclerosis in liver disease 20 (1.6)
Idiopathic glomerulosclerosis 11 (0.9)
Vascular lesions 705 (57.8)
Arterio-arteriolosclerotic scars 672 (55.1)
Infarct scars 14 (1.1)
‘Subinfarct’ scars 9 (0.7)
Contracted kidney due to renal artery stenosis 30 (2.5)
Cholesterol embolism 43 (3.5)
Metabolic lesions 80 (6.6)
Amyloidosis 8 (0.7)
Nephrocalcinosis 67 (5.5)
Uric acid tophi 5 (0.4)
Tubulo-interstitial lesions 113 (9.3)
Analgesic nephropathy 2 (0.2)
Pyelonephritis 92 (7.5)
Hydronephrosis 18 (1.5)
Lithiasis 1 (0.1)
Malformation 12 (1.0)
Polycystic (adult) kidney disease 6 (0.5)
Malformations, others 6 (0.5)
Contracted kidney not specified 5 (0.4)
Table 1. Patient population (n¼ 616) and kidney parameters
(n¼ 1220)
Mean SD Med Range
Age (yr)
Male 73.0 13.1 75 22–98
Female 77.8 12.5 80 20–103
BMI (kg/m2)
Male 24.2 5.3 23.9 11–42
Female 23.4 6.4 22.3 10.5–46.5
Kidney weight, right (g)
Male 152.0 44.1 150 11–310
Female 116.7 50.4 109 37–640
Kidney weight, left (g)
Male 161.4 116.0 155 50–2086
Female 119.4 66.9 110 17–780
S-creatinine (mmol/l)
Male (n¼ 284) 170 150 122 32–950
Female (n¼ 263) 151 132 107 20–950
Table 2. Prevalence of different types of renal lesions in 616 patients/
1220 kidneys
Diagnosis Both sides n (% of kidneys)
No significant lesions 189 (15.5)
Acute lesions 101 (8.3)
Chronic lesions 854 (70)
Pathology of the papilla 175 (14.3)
Pathology of the ureter 19 (1.6)
Tumours 71 (5.8)
Nephrectomy 12 (1a)
aCalculated on the basis of all kidneys (n¼ 1232).
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and the papillary tip. Areactive complete necrosis
of at least one papilla was found in 0.9% of the
kidneys but in only one patient was it associated with
capillary sclerosis of both ureters (Table 5). This was
the single case where a clear diagnosis of analgesic
nephropathy could be made on histological grounds in
the patient’s own kidneys but not in her transplant.
In another transplanted female with a clinical
diagnosis of analgesic nephropathy, due to the abuse
of phenacetin-containing mixed analgesics during
the 1950s and 1960s, not a slightest trace of capillary
sclerosis could be detected. However, her minuscule
contracted kidneys showed histologically complete
areactive papillary necroses (Figure 2 and Table 5).
Fig. 1. Schematic description of the different types of papillary
necrosis.
T
a
b
le
5
.
A
n
a
ly
si
s
o
f
k
id
n
ey
s
w
it
h
co
m
p
le
te
p
a
p
il
la
ry
n
ec
ro
si
s
A
u
to
p
sy
N
r.
S
ex
A
g
e
(y
r)
C
li
n
ic
a
l
d
ia
g
n
o
si
s
S
-c
re
a
ti
n
in
e
(m
m
o
l/
l)
P
a
th
o
lo
g
ic
a
l
d
ia
g
n
o
si
s
C
a
p
il
la
ry
sc
le
ro
si
s
P
a
p
il
la
ry
n
ec
ro
si
s
A
0
0
.5
0
0
F
6
7
B
en
ig
n
/m
a
li
g
n
a
n
t
n
ep
h
ro
sc
le
ro
si
s,
k
id
n
ey
tr
a
n
sp
la
n
t
–
A
n
a
lg
es
ic
n
ep
h
ro
p
a
th
y
Y
es
R
ig
h
t
a
n
d
le
ft
A
0
1
.1
1
7
M
7
9
U
ro
se
p
si
s
1
9
6
C
h
ro
n
P
N
ri
g
h
t/
le
ft
,
v
a
sc
.
sc
a
rs
ri
g
h
t/
le
ft
,
u
ro
th
el
ia
l
b
la
d
d
er
tu
m
o
u
r
N
o
R
ig
h
t
a
n
d
le
ft
A
0
1
.2
8
3
F
7
4
–
1
9
1
C
h
ro
n
P
N
ri
g
h
t,
v
a
sc
.
sc
a
rs
ri
g
h
t/
le
ft
N
o
R
ig
h
t
A
0
1
.3
9
0
M
7
4
–
1
1
9
P
N
ri
g
h
t/
le
ft
w
it
h
o
b
st
ru
ct
io
n
N
o
R
ig
h
t
a
n
d
le
ft
A
0
1
.4
7
6
F
7
9
A
n
a
lg
es
ic
n
ep
h
ro
p
a
th
y
k
id
n
ey
tr
a
n
sp
la
n
t
–
C
h
ro
n
.
P
N
ri
g
h
t/
le
ft
,
u
n
d
ef
.
co
n
tr
a
ct
ed
k
id
n
ey
N
o
R
ig
h
t
a
n
d
le
ft
A
0
2
.0
3
5
F
8
3
–
2
0
4
C
h
ro
n
P
N
ri
g
h
t/
le
ft
,
v
a
sc
.
sc
a
rs
ri
g
h
t
N
o
R
ig
h
t
a
n
d
le
ft
Table 4. Lesions of the renal papilla in 616 patients/1220 kidneys
Diagnosis Both sides n
(% of kidneys)
No significant lesions of the papilla 1045 (85.7)
Fibrosis 90 (7.4)
Focal fibrosis 87 (7.1)
Complete fibrosis 3 (0.2)
Necrosis 102 (8.4)
Areactive necrosis of the papillary tip 56 (4.6)
Areactive focal necrosis 22 (1.8)
Areactive complete necrosis 11 (0.9)
Necrosis in pyelonephritis 13 (1.1)
Others 46 (3.8)
Calcinosis 39 (3.2)
Cystoid dilatation of collecting ducts 2 (0.2)
Haemangioma 1 (0.1)
Amyloidosis of the papilla only 4 (0.3)
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None of the other 614 patients had evidence of
papillary or urothelial capillary sclerosis.
Renal and urothelial malignancies
Among the 616 autopsy cases, a total of 10 patients
had renal cell carcinoma (prior nephrectomy six cases,
at autopsy four cases) and three patients had urothelial
cell carcinomas of the renal pelvis (one prior nephrec-
tomy, two autopsy cases). In addition, four patients
had carcinoma of the bladder. There was one 79-year-
old male with bilateral areactive papillary necrosis,
who had undergone repetitive transurethral resections
for papillary non-invasive bladder carcinoma 6–2 years
before death. In none of the other cases with papillary
necrosis were urothelial tumours detected in the lower
urinary tract.
Discussion
Many analgesic compounds and phenacetin in partic-
ular were produced during the 20th century in the
pharmaceutical metropolis of Basle which thus also
became one of the world centres of analgesic abuse
and its consequence: analgesic nephropathy [34,36].
The pathophysiological chain of events started with
the abuse of phenacetin-containing analgesics which
led to capillary sclerosis in the renal medulla causing
papillary necrosis and consequently tubulo-interstitial
nephropathy with cortical atrophy [27,39]. It could be
of no surprise, therefore, that capillary sclerosis was
detected in 4% of autopsies performed in Basle in
1978–80 [36] when analgesic nephropathy reached its
peak prevalence and was deemed responsible for
end-stage renal disease in over 25% of the Swiss
patients starting renal replacement therapy [33].
The present study of over 600 consecutive autopsies
some 20 years later and also some 20 years after the
disappearance of phenacetin from the analgesic market
delineates a completely changed picture regarding
analgesic nephropathy. Our systematic meticulous
study of renal and urothelial histology detected only
a single case of classic analgesic nephropathy with
complete papillary necrosis in highly contracted
kidneys associated with ureteral capillary sclerosis.
This was the case of a female who would have died
14 years earlier had she not undergone renal replace-
ment therapy including renal transplantation. None of
the other five patients with unilateral or bilateral
complete papillary necrosis had any evidence of
capillary sclerosis. In one of these patients who had
been a known analgesic abuser in the 1950s and 1960s
and who had also undergone renal transplantation
14 years before death, classic analgesic nephropathy
could not be proven because capillary sclerosis
was no longer detectable. According to our earlier
observations, 20–30 years without phenacetin intake is
more than sufficient for capillary sclerosis to recede
completely [27].
Fig. 2. Complete papillary necrosis in patient 1, Table 5. (A–C) Ureter with remnants of capillary sclerosis; (D) papillary necrosis with
massive Tamm–Horsfall protein deposits (strong PAS-positive material).
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The prevalence of primary renal tumours was in
the expected range. However, compared to 1980, the
autopsy prevalence of renal pelvic, ureteral and
bladder carcinomata was much lower in the present
study [40]. This might be due to the disappearance
of carcinogenic metabolites of phenacetin, whereas
paracetamol, the non-carcinogenic but analgesic metab-
olite of phenacetin, continues to be widely used.
All the other histological findings mentioned in the
result section lack surprising features. The high
prevalence of chronic vascular lesions, mainly arterio-
arteriolosclerotic scars, vascular scars due to renal
artery stenosis and cholesterol embolism as well as
the high prevalence of diabetic glomerulosclerosis,
need clinical attention since most of these lesions
may at least partially be prevented by early and
consequent therapy of the underlying conditions such
as hypertension, hyperlipidaemia, diabetes mellitus
and smoking.
As noted earlier, it is—or better, it was—capillary
sclerosis within the renal medulla developing due
to toxic metabolites of phenacetin that was causing
papillary necrosis and thus classic analgesic nephro-
pathy. This initiating toxic event may have preceded
the clinical diagnosis of analgesic nephropathy by
decades. Epidemiological studies relating clinically
diagnosed analgesic nephropathy to the intake of
supposedly toxic drugs consumed during the preceding
5–10 years may thus easily miss earlier or shamefully
unadmitted intake of the notorious phenacetin-
containing analgesics. For this reason and in contrast
to the opinion expressed by one group of Belgian
authors [41], the case appears to be rather weak for
mixed preparations containing analgesics other than
phenacetin to cause chronic renal disease initiated
by papillary necrosis [33,42].
The purpose of the present study was to see whether
removal of phenacetin from analgesic mixtures was
effective in reducing the prevalence of analgesic
nephropathy. As shown in Figure 3, there was a
steady continuous decrease in the prevalence of
analgesic nephropathy in the autopsy statistics of the
Basle Institute of Pathology. This decrease occurred
despite the fact that mixed analgesics have continued
to be popular drugs with paracetamol replacing
phenacetin in many preparations since the 1970s
and particularly since the early 1980s. The last
and single autopsy case of proven classic analgesic
nephropathy, detected only with the present sophisti-
cated histological study at the end of the year 2000,
can thus be taken as further evidence that this
type of chronic renal disease was due to nothing but
phenacetin-containing mixed analgesics. Some 20 years
after the removal of phenacetin from the market,
classic analgesic nephropathy is all but disappearing
and will no longer be a health hazard in the
21st century.
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